TECX TECTONIC THERAPEUTIC INC revenue, earnings and financials
For the quarter ended June 30, 2026, TECTONIC THERAPEUTIC INC reported revenue of n/a, net income of −$22.3M and diluted EPS of −$1.18; for the fiscal year ended December 2025 revenue was n/a.
TECX annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$84.0M, net income −$74.2B (margin n/a), EPS −$4.05
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$58.0M, net income −$58.0B (margin n/a), EPS −$6.83
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$44.6M, net income −$42.8B (margin n/a), EPS −$33.76
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$105M, net income −$106M (margin n/a), EPS −$2.42
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$119M, net income −$119M (margin n/a), EPS −$2.78
TECX quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$22.3M, EPS −$1.18
- Quarter ended Mar 31, 2026: revenue n/a, net income −$25.2M, EPS −$1.34
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$74.1B, EPS −$1.03
- Quarter ended Sep 30, 2025: revenue n/a, net income −$19.0M, EPS −$1.02
- Quarter ended Jun 30, 2025: revenue n/a, net income −$20.0M, EPS −$1.07
- Quarter ended Mar 31, 2025: revenue n/a, net income −$15.9M, EPS −$0.93
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$57.9B, EPS $9.68
- Quarter ended Sep 30, 2024: revenue n/a, net income −$17.7M, EPS −$1.20
- Quarter ended Jun 30, 2024: revenue n/a, net income −$12.7M, EPS −$4.34
- Quarter ended Mar 31, 2024: revenue n/a, net income −$15.2M, EPS −$10.97
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$42.8B, EPS −$17.06
- Quarter ended Sep 30, 2023: revenue n/a, net income −$10.1M, EPS −$7.62
- Quarter ended Jun 30, 2023: revenue n/a, net income −$10.5M, EPS −$8.51
- Quarter ended Mar 31, 2023: revenue n/a, net income −$14.4M, EPS −$0.57
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$25.0M, EPS −$0.58
- Quarter ended Sep 30, 2022: revenue n/a, net income −$23.0M, EPS −$0.52
- Quarter ended Jun 30, 2022: revenue n/a, net income −$28.1M, EPS −$0.64
- Quarter ended Mar 31, 2022: revenue n/a, net income −$29.8M, EPS −$0.68
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$28.2M, EPS −$0.64
- Quarter ended Sep 30, 2021: revenue n/a, net income −$32.6M, EPS −$0.75
TECX cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$60.1M, share buybacks n/a, dividends $0.00 per share
- Fiscal year ended Dec 2024: operating cash flow −$59.1M, share buybacks n/a, dividends $0.00 per share
- Fiscal year ended Dec 2023: operating cash flow −$40.7M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$97.2M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$98.0M, share buybacks n/a
TECX balance sheet
- Jun 30, 2026: cash $227M, total assets $237M, total liabilities $13.2M, shareholders' equity $224M
- Mar 31, 2026: cash $237M, total assets $247M, total liabilities $16.2M, shareholders' equity $230M
- Dec 31, 2025: cash $254M, total assets $261M, total liabilities $9.71M, shareholders' equity $251M
- Sep 30, 2025: cash $268M, total assets $277M, total liabilities $9.47M, shareholders' equity $268M
- Jun 30, 2025: cash $287M, total assets $295M, total liabilities $11.5M, shareholders' equity $284M
- Mar 31, 2025: cash $306M, total assets $315M, total liabilities $13.8M, shareholders' equity $301M
- Dec 31, 2024: cash $141M, total assets $153M, total liabilities $12.1M, shareholders' equity $141M
- Sep 30, 2024: cash $159M, total assets $169M, total liabilities $18.4M, shareholders' equity $150M
Is TECX profitable?
No. TECTONIC THERAPEUTIC INC lost $74.2B over the last four quarters.
What is TECX's EPS?
Diluted earnings per share over the last four quarters were −$4.57; −$1.18 in the latest quarter.